Table 2 EULAR response, IL-33 detectability rates and association between IL-33 detection and response to tumor necrosis factor inhibitor (TNFi; including adalimumab, certolizumab, etanercept and infliximab) and non-TNFi (including abatacept, rituximab, and tocilizumab) in patients from the ROC study
Treatment | Number of patients | Number of EULAR responders (%) | Number of detectable IL-33 among all patients (%) | Number of detectable IL-33 among EULAR responders (%) | Association between IL-33 detectability and EULAR response (OR [95% CI]) | |
|---|---|---|---|---|---|---|
TNFi | Adalimumab | 53 | 30 (56.6) | 23 (43.4) | 14 (46.7) | 1.4 [0.5–4.1] |
Etanercept | 49 | 29 (59.2) | 20 (40.8) | 13 (44.8) | 1.5 [0.5–5.0] | |
Certolizumab | 23 | 10 (43.5) | 10 (43.5) | 5 (50.0) | 1.6 [0.3–8.5] | |
Infliximab | 8 | 1 (12.5) | 3 (37.5) | 1 (100) | 6.6 [0.2–226] | |
Total TNFi | 133 | 70 (52.6) | 56 (42.1) | 33 (47.1) | 1.6 [0.8–3.1] | |
Non-TNFi | Rituximab | 37 | 20 (54.0) | 10 (27.0) | 6 (30.0) | 1.4 [0.3–6.1] |
Abatacept | 30 | 18 (60.0) | 11 (36.6) | 8 (44.4) | 2.4 [0.5–11.9] | |
Tocilizumab | 67 | 53 (79.1) | 32 (47.8) | 25 (47.2) | 0.9 [0.3–2.9] | |
Total non-TNFi | 134 | 91 (67.9) | 53 (39.6) | 39 (42.9) | 1.6 [0.7–3.3] |